Document is current
Any future updates will be listed below
-
Authors
Rodríguez-Pallares, Salud
González-Pinto, Lucía
Tarriño-León, María
Aja-Macaya, Pablo
Sánchez-Peña, Lucía
Moscoso, Miriam
Pérez-Rodríguez, Gloria
Blanco-Martín, Tania
Beceiro, Alejandro
Bou, Germán
Arca-Suárez, Jorge
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (CM23/00104)
Instituto de Salud Carlos III (FI23/00074)
Instituto de Salud Carlos III (PI22/01212)
Instituto de Salud Carlos III (CM23/00095)
Instituto de Salud Carlos III (PI23/00851)
Instituto de Salud Carlos III (PI24/00920)
Instituto de Salud Carlos III (JR21/00026)
Fundación Publica Galega de investigación Biomédica (INIBIC) and Xunta de Galicia (IN606A 2024/022)
Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CB21/13/00055)
Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CB21/13/00055)
Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CB21/13/00055)
Axencia Galega de Innovación (IN607D 2021/12)
Axencia Galega de Innovación (IN607A 2024/09)
Axencia Galega de Innovación (IN607D 2024/008)
- License Information
-
More Information
Article History
Received: 14 May 2025
Accepted: 31 October 2025
First Online: 11 November 2025
Declarations
:
: G.B. has received funding and study materials from MSD, grants contracts from MSD, Pfizer, ABAC Therapeutics and Roche, consulting fees and honoraria for lectures and/or presentations from MSD, Shionogi Pfizer, Roche and Menarini, and support for attending meetings and/or travels from Pfizer. J.A.-S. has received honoraria for lectures, consulting fees and/or presentations from MSD, Shionogi, Pfizer, and Advanz Pharma. All other authors: none to declare.
